Loading
Life sciences · Journal article
Biochimica Et Biophysica Acta. Molecular Basis of Disease · September 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Disordered lipid metabolism and inflammation, the hallmark features of metabolic dysfunction-associated steatohepatitis (MASH), present a significant therapeutic challenge even in the absence of obesity, making the discovery of novel pathogenic mechanisms and therapies imperative. Although Celastrol (Cel) markedly ameliorates high-fat diet (HFD)-induced obesity, whether and by what molecular basis it directly ameliorates hepatic inflammation and disordered lipid metabolism remains unclear. Here, using a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced MASH model, we demonstrate that Cel ameliorates steatohepatitis and identify CD36 in liver sinusoidal endothelial cells (LSECs)-the key gatekeepers of hepatic immunometabolic homeostasis-as the central mediator coordinating hepatic lipid transport and inflammatory responses. Elucidating the regulatory mechanism, we found that USP12 removes K48-linked ubiquitination from CD36 and stabilizes it in LSECs. Cel downregulates USP12, thereby promoting CD36 ubiquitination and subsequent degradation, which in turn attenuates chemokine-driven macrophage recruitment and suppresses pathological lipid transport. The clinical relevance of this axis is supported by the concurrent upregulation of both USP12 and CD36 in human livers with steatohepatitis. These findings reveal that LSEC heterogeneity orchestrates hepatic metabolism and inflammation via the USP12/CD36 axis, designating it a therapeutic target for interventions with agents such as Cel.